10-Q: Relay Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Relay Therapeutics reports a net loss of $92.2 million for the second quarter of 2024, while highlighting progress in clinical trials and discovery programs.

Summary

• Relay Therapeutics, a clinical-stage precision medicine company, announced its financial results for the second quarter of 2024, reporting a net loss of $92.2 million, or $0.69 per share.
• The company's total revenue for the quarter was $0, compared to $0.1 million in the same period last year, with a significant increase in revenue for the six months ended June 30, 2024, at $10.0 million, primarily due to a milestone payment from the Genentech Agreement.
• Research and development expenses for the quarter were $92.0 million, up from $88.2 million in the second quarter of 2023, driven by increased external costs for the ReDiscover Trial of RLY-2608.
• The company's cash, cash equivalents, and investments totaled $688.4 million as of June 30, 2024, which they believe will fund operations into the second half of 2026.
• Relay Therapeutics is advancing clinical trials for RLY-2608 and lirafugratinib (RLY-4008), and has announced three new discovery stage programs in genetic diseases and oncology.
• The company also announced the termination of the Genentech Agreement, which will become effective 180 days after the notice date, resulting in the cessation of further milestone payments and development obligations.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has a strong cash position and is advancing its clinical programs, the significant net loss, the termination of the Genentech agreement, and the need for future capital raises temper the positive aspects. The overall sentiment is cautiously negative due to the financial losses and the loss of a key partnership.

Positives

• Relay Therapeutics has a strong cash position of $688.4 million, which is expected to fund operations into the second half of 2026.
• The company is making progress in its clinical trials for RLY-2608 and lirafugratinib.
• Three new discovery stage programs were announced, expanding the company's pipeline in genetic diseases and oncology.
• The company received a $10.0 million milestone payment from the Genentech Agreement during the six months ended June 30, 2024.

Negatives

• Relay Therapeutics reported a significant net loss of $92.2 million for the second quarter of 2024.
• The company's revenue for the quarter was $0, a decrease from $0.1 million in the same period last year.
• The termination of the Genentech Agreement will result in the loss of future milestone payments and development obligations.
• The company has incurred significant operating losses since its inception and expects to continue to incur losses for the foreseeable future.

Risks

• The company has a limited operating history and has incurred significant losses since its inception.
• Clinical trials are lengthy, expensive, and have uncertain outcomes, with potential delays in enrollment and regulatory approvals.
• Positive data from preclinical or early clinical studies may not predict results of later clinical trials.
• The company faces substantial competition from other pharmaceutical and biotechnology companies.
• The company relies on third parties for clinical trials and manufacturing, which could lead to delays or failures.
• The company will need to raise substantial additional funding, and failure to do so could force delays or reductions in development programs.
• The company's intellectual property may not be adequately protected, allowing competitors to develop similar products.
• The termination of the Genentech Agreement will result in the loss of future milestone payments and development obligations.
• The company is subject to risks associated with operating as a public company, including compliance costs and potential litigation.

Future Outlook

The company believes its existing cash, cash equivalents, and investments will enable it to fund operating expenses and capital expenditure requirements into the second half of 2026. They expect to continue to incur significant operating losses for the foreseeable future and will need to raise additional capital.

Management Comments

• Management believes that the interim clinical data from the ReDiscover Trial support selective target engagement across doses and mutation types with an encouraging interim safety and tolerability profile.
• Management believes that the interim clinical data from the ReFocus Trial show interim efficacy signals in the CCA pan-FGFR treatment-naive, FGFR2-fusion CCA cohort and non-CCA solid tumor expansion cohorts.

Industry Context

The announcement reflects the ongoing challenges and high costs associated with drug development in the biotechnology industry, particularly for companies focused on precision medicine. The termination of the Genentech collaboration highlights the risks of relying on partnerships and the need for companies to maintain control over their development programs. The company's focus on novel mechanisms of action and novel binding locations is consistent with the industry's push for innovative therapies, but also carries higher risks and uncertainties.

Comparison to Industry Standards

• Relay Therapeutics' cash position of $688.4 million is relatively strong compared to many other clinical-stage biotech companies, providing a runway into the second half of 2026.
• The reported net loss of $92.2 million for the quarter is significant, but not uncommon for companies in this stage of development, which typically have high R&D expenses and no product revenue.
• The increase in R&D expenses to $92.0 million reflects the company's focus on advancing its clinical programs, which is consistent with industry trends for companies with promising clinical candidates.
• The termination of the Genentech collaboration is a setback, but it is not unusual for such agreements to be terminated, and the company's ability to continue development of its programs will be a key factor in its future success.
• The company's focus on precision medicine and novel mechanisms of action aligns with current industry trends, but also carries higher risks and uncertainties compared to companies developing more established therapies.

Stakeholder Impact

• Shareholders will be impacted by the net loss and the termination of the Genentech agreement, which may affect the stock price.
• Employees will be impacted by the company's need to manage growth and potential changes in strategy.
• Patients may benefit from the company's continued development of new therapies, but the timeline for approval and commercialization remains uncertain.
• Suppliers and partners may be impacted by the company's need to manage costs and potential changes in strategy.

Next Steps

• The company will continue to advance its clinical trials for RLY-2608 and lirafugratinib.
• The company will continue to develop its three new discovery stage programs.
• The company will need to secure additional funding to support its ongoing operations and development programs.
• The company will need to evaluate the impact of the Genentech Agreement termination on its future strategy.

Key Dates

Keywords

Relay Therapeutics, clinical trials, precision medicine, RLY-2608, lirafugratinib, FGFR2, PI3K, oncology, genetic diseases, biopharmaceutical, drug discovery, financial results